Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MME | P08473 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 1/20 | 0.51 |
| ▸ | LAP3 | P28838 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | FNTA | P49354 | 1/20 | 0.46 |
| ▸ | FNTB | P49356 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9545240 | 1.00 | ALDH1A1 (0.55) | ALDH1A1MMEMEN1LMNAKMT2A | |
| SCHEMBL29566961 | 0.92 | MME (0.49) | ALDH1A1MMEMEN1LMNAKMT2A | |
| SCHEMBL30011110 | 0.92 | ACE (0.56) | ALDH1A1MMEMEN1LMNAKMT2A | |
| SCHEMBL30010902 | 0.92 | ACE (0.56) | ALDH1A1MMEMEN1LMNAKMT2A | |
| SCHEMBL30010855 | 0.92 | ACE (0.56) | ALDH1A1MMEMEN1LMNAKMT2A | |
| SCHEMBL30010989 | 0.92 | ACE (0.56) | ALDH1A1MMEMEN1LMNAKMT2A | |
| SCHEMBL29714714 | 0.91 | FNTA (0.48) | ALDH1A1MMEMEN1LMNAKMT2A | |
| SCHEMBL31469847 | 0.90 | MME (0.46) | ALDH1A1MMEMEN1LMNAKMT2A | |
| SCHEMBL31720932 | 0.89 | ACE (0.51) | ALDH1A1MMEMEN1LMNAKMT2A | |
| SCHEMBL29893864 | 0.89 | FOLH1 (0.58) | ALDH1A1MMEFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270610-A1 | Improving the Efficiency of PAL-Catalyzed Protein Ligation By A Cascade Enzymatic Scheme | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2025-08-28 | — | — | US | disclosed |
| US-20250257095-A1 | METHOD FOR VISIBLE LIGHT-MEDIATED CHEMICAL MODIFICATION OF POLYPEPTIDE AND PROTEIN BASED ON CYSTEINE | SHANGHAI JIAO TONG UNIVERSITY (CN) | 2025-08-14 | — | — | US | disclosed |
| EP-4545545-A1 | VISIBLE LIGHT-MEDIATED CYSTEINE-BASED POLYPEPTIDE AND PROTEIN CHEMICAL MODIFICATION METHOD | Shanghai Jiao Tong University (CN) | 2025-04-30 | — | — | EP | disclosed |
| EP-4499858-A1 | IMPROVING THE EFFICIENCY OF PAL-CATALYZED PROTEIN LIGATION BY A CASCADE ENZYMATIC SCHEME | Nanyang Technological University (SG) | 2025-02-05 | — | — | EP | disclosed |
| CN-119234043-A | PAL-catalytic protein ligation efficiency by cascade enzymatic method | 南洋理工大学 | 2024-12-31 | — | — | CN | disclosed |
| CN-117999279-A | Peptides for anti-fibrotic therapy | 麦克马斯特大学 | 2024-05-07 | — | — | CN | disclosed |
| WO-2024007714-A1 | VISIBLE LIGHT-MEDIATED CYSTEINE-BASED POLYPEPTIDE AND PROTEIN CHEMICAL MODIFICATION METHOD | 上海交通大学 | 2024-01-11 | — | — | WO | disclosed |
| CN-117343124-A | Visible light mediated cysteine-based polypeptides and protein chemical modification methods | 上海交通大学 | 2024-01-05 | — | — | CN | disclosed |
| WO-2023191726-A1 | IMPROVING THE EFFICIENCY OF PAL-CATALYZED PROTEIN LIGATION BY A CASCADE ENZYMATIC SCHEME | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2023-10-05 | — | — | WO | disclosed |
| CN-113603681-B | Compound based on cyanine dye and preparation method and application thereof | 湖北大学 | 2023-03-24 | — | — | CN | disclosed |
| CN-113603681-B | Compound based on cyanine dye and preparation method and application thereof | 湖北大学 | 2023-03-24 | — | — | CN | disclosed |
| EP-2610338-A1 | METHOD FOR PRODUCING SUBSTANCE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2013-07-03 | — | — | EP | disclosed |
| US-20130130317-A1 | METHOD FOR PRODUCING SUBSTANCE | KYOWA HAKKO KIRIN CO., LTD (JP) | 2013-05-23 | — | — | US | disclosed |
| WO-1993021211-A1 | AMIDES HAVING INHIBITING ACTIVITY ON PHOSPHOLIPASE A2, A PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LABORATORIOS MENARINI S.A. (ES) | 1993-10-28 | — | — | WO | disclosed |
| US-4866180-A | MITOMYCIN ANALOGS; ANTITUMOR AGENTS | BRISTOL-MYERS COMPANY (US) | 1989-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270610-A1 | Improving the Efficiency of PAL-Catalyzed Protein Ligation By A Cascade Enzymatic Scheme | QPCT, GLUL, QPCTL | ALDH1A1 4141/4885MME 1340/4885MEN1 2312/4885 |
| US-20250257095-A1 | METHOD FOR VISIBLE LIGHT-MEDIATED CHEMICAL MODIFICATION OF POLYPEPTIDE AND PROTEIN BASED ON CYSTEINE | PTMS, CTH, CISD1 | ALDH1A1 2160/4885MME 1398/4885MEN1 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.